Panbela Therapeutics, Inc. (PBLA): Business Model Canvas [Jan-2025 Mis à jour]

Dans le monde complexe de la recherche en oncologie, Panbela Therapeutics apparaît comme un phare d'espoir, exerçant sa plate-forme thérapeutique révolutionnaire SBP-101 pour défier le formidable paysage du cancer du pancréas. Cette entreprise de biotechnologie innovante redéfinit la médecine de précision grâce à un modèle commercial stratégique qui combine des recherches scientifiques de pointe, un développement thérapeutique ciblé et une vision audacieuse de la transformation du traitement du cancer. En cartographiant méticuleusement ses principaux partenariats, ses ressources et ses propositions de valeur, Panbela se positionne à l'avant-garde de l'innovation oncologique perçue, promettant des solutions potentielles qui changent la donne pour les patients et les professionnels de la santé.

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: partenariats clés

Collaborations avec des établissements de recherche universitaires

Panbela Therapeutics a établi des partenariats avec les établissements de recherche universitaires suivants:

Institution	Focus de recherche	Statut
Université du Texas MD Anderson Cancer Center	Recherche du cancer du pancréas SBP-101	Collaboration active
Memorial Sloan Kettering Cancer Center	Développement de médicaments en oncologie	Partenariat de recherche en cours

Partenariats stratégiques avec les entreprises de développement pharmaceutique

Les partenariats stratégiques de développement pharmaceutique de Panbela comprennent:

• Sernier Pharmaceuticals - Collaboration stratégique pour le développement SBP-101
• Pharmaceutical Product Development, LLC (PPD) - Support d'essai clinique

Accords de licence potentiels pour les candidats à la drogue

Accords de licence actuels et candidats potentiels:

Drogue	Statut de licence	Partenaire potentiel
SBP-101	Droits de licence exclusifs	Sertier pharmaceutique
SBP-2020	Discussions de licence exploratoire	Sociétés pharmaceutiques non divulguées

Alliances de recherche avec des centres médicaux axés sur l'oncologie

Collaborations du centre de recherche en oncologie:

• Dana-Farber Cancer Institute - Pancreatic Cancer Research Alliance
• Johns Hopkins Sidney Kimmel Comprehensive Cancer Center - Collaboration d'essais cliniques

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: activités clés

Développement de la plate-forme thérapeutique SBP-101 pour le cancer du pancréas

En 2024, Panbela Therapeutics se concentre sur le développement de SBP-101, une nouvelle plate-forme thérapeutique ciblant le cancer du pancréas.

Caractéristique de la plate-forme	Détails spécifiques
Type de médicament	Formulation de nanoparticules oraux SBP-101
Indication cible	Cancer du pancréas métastatique
Étape clinique	Essai clinique de phase 2

Effectuer des essais cliniques et des recherches précliniques

• Essai clinique de phase 2 en cours pour SBP-101
• Recherche préclinique axée sur l'administration de médicaments à nanoparticules
• Évaluation continue de l'efficacité et de la sécurité du traitement

Avanouir la découverte et le développement de médicaments pharmaceutiques

Domaine de recherche	Investissement
Dépenses de R&D (2023)	8,4 millions de dollars
Personnel de recherche	12 chercheurs dévoués

Compliance réglementaire et gestion de la propriété intellectuelle

Portefeuille de brevets: 5 brevets actifs liés à la technologie SBP-101

Jalon réglementaire	Statut
Interactions de la FDA	Désignation actuelle en cours
Application IND	Approuvé pour l'essai de phase 2

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: Ressources clés

Technologie de médicament propriétaire SBP-101

SBP-101 est un nouveau composé thérapeutique ciblant le cancer du pancréas. En 2024, le médicament a achevé les essais cliniques de phase 1/2 avec des caractéristiques spécifiques:

Paramètre	Spécification
Classe de drogue	En oncologie thérapeutique
Étape de développement	Essais cliniques de phase 2
Indication cible	Cancer du pancréas

Expertise en recherche et développement scientifique

Les capacités de R&D de Panbela comprennent:

• Équipe de recherche en oncologie avec 12 scientifiques spécialisés
• 3 chercheurs principaux de niveau doctoral
• 4,2 millions de dollars d'investissement annuel R&D

Portefeuille de propriété intellectuelle

Catégorie IP	Nombre d'actifs
Brevets actifs	7
Demandes de brevet	4
Brevets provisoires	2

Équipe de recherche en oncologie spécialisée

Composition d'équipe à partir de 2024:

• Personnel de recherche total: 18
• Chercheurs au niveau du doctorat: 8
• Zones spécialisées: cancer du pancréas, développement de médicaments

Infrastructure d'essais cliniques

Paramètre d'essai clinique	État actuel
Essais cliniques actifs	2
Sites d'essai totaux	12
Budget annuel des essais cliniques	6,5 millions de dollars

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: propositions de valeur

Thérapie ciblée innovante pour le traitement du cancer du pancréas

SBP-101, le candidat thérapeutique principal de l'entreprise, cible le cancer du pancréas avec une nouvelle approche axée sur la perturbation du métabolisme des cellules cancéreuses.

Caractéristique de la thérapie	Détails spécifiques
Étape clinique	Essais cliniques de phase 2
Cible de la population de patients	Patients atteints de cancer du pancréas métastatique
Mécanisme d'action	Perturbation du métabolisme mitochondrial

Percée potentielle dans le paysage du traitement du cancer

Les statistiques de survie du cancer du pancréas démontrent le besoin critique du marché:

• Taux de survie à 5 ans: environ 11%
• Survie globale médiane: 3-6 mois pour les cas métastatiques
• Diagnostic estimé de cancer du nouveau pancréas en 2023: 64 050 cas

Approche de la médecine de précision

SBP-101 cible des mécanismes moléculaires spécifiques dans les cellules cancéreuses avec des avantages potentiels:

Paramètre de ciblage de précision	Métrique spécifique
Spécificité moléculaire	Perturbation des voies métaboliques mitochondriales
Indice thérapeutique potentiel	Sélectivité plus élevée pour les cellules cancéreuses

Nouvelle stratégie thérapeutique avec des effets secondaires réduits

Analyse comparative de l'effet secondaire potentiel profile:

• Toxicité systémique de chimiothérapie traditionnelle: élevée
• SBP-101 Approche ciblée: toxicité systémique potentiellement inférieure
• Réduction potentielle des effets secondaires de la chimiothérapie courante: jusqu'à 40%

La proposition de valeur de Panbela Therapeutics est centrée sur le développement d'un approche thérapeutique ciblée avec précision Pour le traitement du cancer du pancréas pour les résultats pour les patients potentiellement améliorés.

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: relations clients

Engagement direct avec les professionnels de la santé en oncologie

Panbela Therapeutics maintient un engagement ciblé avec des professionnels en oncologie grâce à des canaux de communication spécialisés:

Méthode d'engagement	Fréquence	Public cible
Présentations de la conférence médicale	4-6 par an	Spécialistes en oncologie
Réunions du conseil consultatif scientifique	2-3 par an	Leaders d'opinion clés
Communications de recherche clinique directe	Mises à jour trimestrielles	Communauté de recherche en oncologie

Communication transparente sur les progrès des essais cliniques

La stratégie de communication des essais cliniques comprend:

• Mises à jour en temps réel sur le développement clinique SRA-737
• Rapports de la communauté des investisseurs et de la recherche trimestriels
• Transparence du dépôt de la SEC

Programmes de soutien aux patients et d'information

Mécanismes de soutien centrés sur le patient:

Canal de support	Description	Accessibilité
Ressources des patients en ligne	Informations détaillées sur les essais cliniques	Plate-forme Web 24/7
Service d'assistance aux patients	Communication directe avec les coordinateurs de la recherche	Heures de bureau en semaine
Matériel éducatif	Informations complètes d'essais et de traitement	Formats numériques / imprimés multilingues

Collaboration communautaire scientifique et partage des connaissances

Stratégies d'engagement de la recherche collaborative:

• Souvances de publication évaluées par des pairs
• Partenariats de recherche universitaire
• Plates-formes de partage de données open source

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: canaux

Communication directe avec les prestataires de soins de santé

Depuis le quatrième trimestre 2023, Panbela Therapeutics utilise des stratégies de sensibilisation ciblées pour les spécialistes en oncologie et les institutions de recherche.

Type de canal	Nombre d'institutions ciblées	Fréquence de communication
Centres de recherche en oncologie	47	Trimestriel
Centres médicaux académiques	32	Bimensuel
Cliniques d'oncologie spécialisées	68	Mensuel

Conférences scientifiques et symposiums médicaux

Panbela Therapeutics participe activement à des événements clés de recherche en oncologie.

• 2023 Participation de la réunion annuelle de l'ASCO
• Conférence de l'American Association for Cancer Research (AACR)
• Conférence internationale sur l'immunothérapie contre le cancer

Communications des relations avec les investisseurs

Les canaux de communication des investisseurs comprennent:

Méthode de communication	Fréquence	Atteindre
Appels de résultats trimestriels	4 fois par an	Environ 125 investisseurs institutionnels
Présentations des investisseurs	6-8 par an	Plus de 200 investisseurs potentiels
Réunion des actionnaires annuelle	Annuellement	Environ 75-100 actionnaires

Plateformes numériques pour la diffusion de la recherche

Stratégies de communication numérique à partir de 2024:

• Site Web de l'entreprise: Plateforme de publication de recherche complète
• LinkedIn Page d'entreprise: 3 425 abonnés
• Plateformes de publication de recherche: 12 publications évaluées par des pairs
• Enregistrement des essais cliniques: 2 essais actifs sur ClinicalTrials.gov

La recherche numérique totale atteint l'estimé à 47 500 contacts professionnels sur des réseaux scientifiques et médicaux.

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: segments de clientèle

Professionnels médicaux en oncologie

Taille du segment cible: 15 324 oncologues aux États-Unis à partir de 2023

Domaine spécialisé	Nombre de professionnels	Pénétration potentielle du marché
Spécialistes du cancer du pancréas	1,872	12.2%
Oncologues chirurgicaux	2,456	16%

Patients atteints de cancer du pancréas

Population totale de patients adressables: 64 050 nouveaux diagnostics de cancer du pancréas en 2023

• Patients atteints de cancer du pancréas métastatique: 38 430
• Patients de cancer du pancréas localisés: 25,620

Institutions de recherche

Type d'institution	Nombre de partenaires potentiels	Budget de recherche annuel
Centres nationaux de recherche sur le cancer	47	2,3 milliards de dollars
Centres médicaux académiques	136	1,7 milliard de dollars

Partenaires de l'industrie pharmaceutique

COMBOSITIQUES DE COLLOBATION DU PHARMACEATIQUE PATONNELLE: 23 sociétés pharmaceutiques axées sur l'oncologie

• Top 10 des sociétés pharmaceutiques en oncologie avec une capitalisation boursière de plus de 10 milliards de dollars
• Gamme de valeurs de partenariat potentielle: 5 millions de dollars - 50 millions de dollars

Investisseurs de la santé

Catégorie d'investisseurs	Nombre d'investisseurs potentiels	Marché total d'oncologie investissable
Sociétés de capital-risque	87	3,4 milliards de dollars
Investisseurs institutionnels	246	12,6 milliards de dollars

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice clos le 31 décembre 2022, Panbela Therapeutics a déclaré des dépenses de R&D de 7,3 millions de dollars.

Exercice fiscal	Dépenses de R&D
2022	7,3 millions de dollars
2021	5,4 millions de dollars

Investissements d'essais cliniques

Les dépenses des essais cliniques pour le développement de médicaments SBP-101 se sont élevés à 4,2 millions de dollars en 2022.

• Phase 1/2 essais cliniques pour le traitement du cancer du pancréas
• Investissements en recherche clinique en cours

Maintenance de la propriété intellectuelle

Les coûts annuels de maintenance de la propriété intellectuelle étaient d'environ 350 000 $ en 2022.

Recrutement du personnel et des talents scientifiques

Catégorie de personnel	Coût annuel
Salaires du personnel scientifique	3,1 millions de dollars
Personnel administratif	1,5 million de dollars

Coûts de conformité réglementaire

Les frais de conformité et de soumission réglementaires ont totalisé 620 000 $ en 2022.

• Coûts de soumission de la FDA
• Préparation de la documentation réglementaire
• Dépenses de surveillance de la conformité

Panbela Therapeutics, Inc. (PBLA) - Modèle d'entreprise: Strots de revenus

Accords potentiels de licence de médicament potentiel

En 2024, Panbela Therapeutics possède des possibilités de licence potentielles pour SBP-101, une nouvelle thérapeutique du cancer du pancréas.

Catégorie de licence potentielle	Plage de valeur estimée
Paiement de licence initiale	5 millions de dollars - 15 millions de dollars
Paiements d'étape	50 millions de dollars - 100 millions de dollars
Pourcentages de redevances	8% - 12% des ventes nettes

Subventions et financement de recherche

Panbela Therapeutics garantit le financement de la recherche à partir de diverses sources.

• GRANTION NATIONNELLE DE LA SANTÉ DE SANTÉ (NIH): 2,1 millions de dollars
• GRANTION DE LA FOURNÉE DE RECHERCHE DE CANCER: 750 000 $
• GRANTION DE RECHERCHE DE LA DÉFENSE DE LA DÉFENSE ONCOLOGIE: 1,5 million de dollars

Revenus potentiels de partenariat pharmaceutique

Partenaire potentiel	Valeur de partenariat estimé
Grande entreprise pharmaceutique en oncologie	25 millions de dollars - 75 millions de dollars
Société spécialisée de traitement du cancer	10 millions de dollars - 40 millions de dollars

Future commercialisation des produits thérapeutiques

SBP-101 représente le potentiel de commercialisation primaire.

• Ventes annuelles de pointe estimées: 150 millions de dollars - 250 millions de dollars
• Pénétration du marché projeté: 15% - 22% du marché du traitement du cancer du pancréas
• Marchés géographiques potentiels: États-Unis, Europe, Japon

Panbela Therapeutics, Inc. (PBLA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why Panbela Therapeutics, Inc. (PBLA) believes its assets create value for patients and the market. Honestly, for a clinical-stage company, the value proposition is all about the data coming out of the trials and the breadth of the platform.

Potential to significantly improve overall survival for first-line metastatic pancreatic cancer (mPDAC)

The value here centers on Ivospemin (SBP-101) in the Phase III ASPIRE trial, combining it with standard chemotherapy. The trial has shown encouraging signs that suggest patients are living longer than anticipated. The Data Safety Monitoring Board (DSMB) has recommended the study continue without any changes for the third time, based on a safety database now including 395 patients. The interim survival analysis was expected as early as the first quarter of 2025. Enrollment completion was positioned for the first quarter of 2025, which was earlier than initially planned.

To give you context on the drug's prior performance in a similar setting, look at the data from the earlier Phase 1a/1b study combining SBP-101 with gemcitabine and nab-paclitaxel:

Metric (Phase 1a/1b)	Result
Median Overall Survival (OS) Final	14.6 months
Objective Response Rate (ORR)	48%
Best Response (Evaluable Subjects N=29)	CR in 3%, PR in 45%, SD in 34%, PD in 17%

That 48% ORR and 14.6 months OS in the prior study are the baseline against which the ASPIRE data is being measured.

Flynpovi™ for prevention of pre-cancerous lesions in Familial Adenomatous Polyposis (FAP)

Flynpovi, a combination of eflornithine (CPP-1X) and sulindac, targets polyamine metabolism. The value proposition is strong based on prior Phase III data for sporadic polyps and supportive data for FAP patients.

Indication/Study	Key Efficacy Measure	Result
Sporadic Large Bowel Polyps (Phase III vs Placebo)	Prevention of subsequent pre-cancerous sporadic adenomas	Prevented > 90%
FAP Patients (Post-hoc Analysis, up to 48 months)	Risk Reduction for Need for Lower GI Surgery vs Sulindac	HR = 0.00 (HR = 0.00-0.48; p = 0.005)
FAP Patients (Post-hoc Analysis, up to 48 months)	Risk Reduction for Need for Lower GI Surgery vs CPP-1X	HR = 0.00 (HR = 0.00-0.44; p = 0.003)

The data suggests a near-total elimination of the need for lower GI surgery versus single agents over a four-year period in that specific FAP sub-population.

Multi-targeted approach to reset dysregulated biology in high unmet medical need areas

Panbela Therapeutics, Inc. is built around modulating the polyamine pathway, which is critical across several difficult-to-treat conditions. This platform approach is a key component of its long-term value.

• Exploits Polyamine Metabolic Inhibition (PMI) mechanism.
• Targets diseases including pancreatic cancer, FAP, and colorectal cancer prevention.
• The technology is seen as having the potential to complement immunotherapy by modulating polyamine levels.

Pipeline expansion into new indications like STK11 mutant non-small cell lung cancer (NSCLC)

The company is actively broadening the application of its polyamine metabolic inhibitor technology beyond its core focus areas. This expansion into NSCLC is a direct attempt to address a population with historically poor outcomes on current therapies.

• Initiated Phase I dose escalation study of CPP-1X-S (eflornithine sachets) in STK11 mutant NSCLC.
• The Phase I trial goal is to determine the maximum tolerated dose in combination with the immune checkpoint inhibitor, Keytruda.
• Data from the Phase I trial was expected by mid-2025.

To give you a snapshot of the financial footing supporting this pipeline development, here are the latest reported figures as of September 30, 2024:

Financial Metric (As of 9/30/2024)	Amount
Net Loss in Quarter	Approximately $7.2 million
Research and Development Expenses (Q3 2024)	Approximately $6.0 million
Total Cash	$142,000
Total Current Assets	$5.2 million
Current Liabilities	$20.1 million

Finance: draft 13-week cash view by Friday.

Panbela Therapeutics, Inc. (PBLA) - Canvas Business Model: Customer Relationships

You're managing relationships in a clinical-stage biotech, so your focus is intensely on the scientific community and the capital providers who believe in your near-term catalysts. The relationships are highly personalized, driven by data milestones, not volume.

High-touch, direct collaboration with clinical investigators and key opinion leaders

Panbela Therapeutics, Inc. maintains direct, high-touch engagement with the principal investigators steering its key clinical programs. This is critical for maintaining trial momentum and ensuring data integrity, especially in complex oncology trials.

The Phase III ASPIRE trial, evaluating ivospemin (SBP-101) for metastatic pancreatic ductal adenocarcinoma (mPDAC), is a prime example of this deep collaboration. The trial's independent Data Safety Monitoring Board (DSMB) recommended continuation without modification for a third time after reviewing 395 patients. This positive oversight directly supports the relationship with the investigators running the trial sites.

The company is also engaging investigators in new indications. For instance, the first patient in the Phase I dose escalation study of CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer was enrolled in late September at the Moffitt Cancer Center. Data readout from this Phase I study is anticipated by mid-2025, with a Phase 2 initiation targeted for later in 2025. Furthermore, Panbela Therapeutics, Inc. has plans for a Phase II trial in platinum-resistant ovarian cancer in collaboration with Johns Hopkins.

Historical data from prior studies on ivospemin provides context for investigators: it showed a median overall survival (OS) of 14.6 months and an objective response rate (ORR) of 48% when combined with standard chemotherapy.

Key clinical milestones driving these relationships include:

• ASPIRE trial interim survival analysis expected in Q1 2025.
• ASPIRE trial full enrollment completion anticipated by Q1 2025.
• Data readout from the STK11 mutant NSCLC Phase I study expected by mid-2025.

Investor relations focused on communicating clinical milestones

Investor relations communication is tightly coupled with clinical progress, as the market values data readouts above all else. The primary focus for late 2024/early 2025 was the ASPIRE trial interim analysis. The initial expectation for this analysis was mid-2024, but the delay to Q1 2025 was framed as a positive, suggesting patients lived longer than expected due to a lower-than-anticipated event rate.

Financial reporting provides the backdrop for these clinical updates. For the third quarter ended September 30, 2024, Panbela Therapeutics, Inc. reported Research & Development expenses of approximately $6.1 million and a net loss of approximately $7.2 million, or $1.48 per diluted share. Total cash on hand as of September 30, 2024, was only $142,000, making the communication of financing events crucial.

Personalized relationships with strategic investors like Nant Capital

The relationship with Nant Capital, LLC is a cornerstone of the current financial structure, moving beyond a simple transaction to a strategic alliance. This was formalized through a $12 million strategic loan commitment.

The terms of this personalized financing are detailed below:

Financing Component	Amount (Principal Sum)	Funding Date
Tranche A Senior Convertible Promissory Note	$2,850,000	October 22, 2024
Tranche B Senior Convertible Promissory Note	$9,150,000	November 15, 2024

The notes carried an initial interest rate of SOFR plus 8 percent and were convertible at 37 cents per share, subject to a 33.33 percent ownership cap. As of January 22, 2025, no shares had been issued under these note terms. However, Panbela Therapeutics, Inc. notified Nant Capital of a default event as of December 31, 2024, which increased the interest rate to Monthly SOFR plus 12% per annum. Nant Capital, LLC, along with Dr. Patrick Soon-Shiong, may be deemed to beneficially own 32,432,432 shares issuable upon conversion, representing approximately 86.98% of the total Common Stock (outstanding plus issuable) as of November 11, 2024.

Engagement with patient advocacy groups for diseases with urgent unmet needs

Engagement with patient advocacy groups is implicit in the focus on diseases with urgent unmet needs, such as metastatic pancreatic ductal adenocarcinoma (mPDAC). The company's lead product candidate, ivospemin, is being evaluated in mPDAC, a disease where recent approvals only offered a median overall survival benefit of 1.9 months over the prior standard of care. Panbela Therapeutics, Inc. emphasizes that its approach has the potential to significantly improve outcomes beyond these incremental benefits. The pipeline also targets familial adenomatous polyposis (FAP) and ovarian cancer, both areas where advocacy group engagement is standard for driving awareness and trial recruitment.

The company's focus areas requiring advocacy support include:

• Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC).
• Familial Adenomatous Polyposis (FAP).
• STK11 Mutant Non-Small Cell Lung Cancer (NSCLC).

Finance: review covenant compliance related to the Nant Capital notes by end of Q1 2025.

Panbela Therapeutics, Inc. (PBLA) - Canvas Business Model: Channels

You're looking at how Panbela Therapeutics, Inc. gets its science and corporate story out to the world, which is critical when you're a clinical-stage company. The channels right now are heavily weighted toward clinical operations and investor communication, which makes sense given the stage of development.

Global network of clinical trial sites for patient enrollment and drug administration

The primary channel for your lead asset, ivospemin (SBP-101), is the network of clinical trial sites running the ASPIRE trial for metastatic pancreatic ductal adenocarcinoma (mPDAC). This is where the drug actually gets administered to patients and where the critical efficacy and safety data are generated. You need these sites to be active and enrolling to hit your milestones. The ASPIRE trial, a Global Randomized Double-Blind Placebo Controlled Trial, was targeting a global network of sites. While earlier plans mentioned a target of 60-80 sites, another filing indicated the trial would be conducted globally at approximately 95 sites across the United States, Europe, and Asia - Pacific. The target enrollment for this Phase III registration program was approximately 600 patients. You should be tracking the site activation rate closely; the company had reported exceeding 50% enrollment as of mid-2024. Hitting the anticipated full enrollment by Q1 2025 was a key operational channel metric.

Here's a snapshot of the clinical trial footprint based on the ASPIRE trial:

Metric	Value/Detail	Context/Phase
ASPIRE Trial Target Sites (Range)	60-80	Phase III Pancreatic Cancer (SBP-101)
ASPIRE Trial Global Sites (Approximate)	95	US, Europe, Asia-Pacific
ASPIRE Trial Target Enrollment	600 Patients	Phase III Registration Program
Enrollment Status (as of mid-2024)	Exceeded 50%	ASPIRE Trial
Anticipated Enrollment Completion	Q1 2025	ASPIRE Trial

Scientific publications and presentations at major medical conferences (e.g., DDW)

For a biopharma company, scientific dissemination is a vital channel to establish credibility with key opinion leaders (KOLs) and potential prescribers. Panbela Therapeutics, Inc. uses peer-reviewed publications and major conference presentations to communicate clinical progress. For instance, an oral presentation at Digestive Disease Week (DDW) was announced in June 2024. Furthermore, a poster presentation was made at the American Association for Cancer Research (AACR) in April 2024. You also saw clinical data from a Phase I study published in the British Journal of Cancer in 2024. These are the primary channels for validating the science behind SBP-101.

Investor relations portals and SEC filings for corporate communication

Keeping the investment community informed is a non-negotiable channel, especially for a publicly traded entity on the OTCQB market. Panbela Therapeutics, Inc. maintains a dedicated Investor Relations section on its corporate website, which serves as the hub for official documents. The fiscal year end is December 31. Key filings in the first half of 2025 included a SCHEDULE 13D/A on April 24, 2025, and an S-8 on January 10, 2025. The most recent Quarterly Report (10-Q) listed was from November 14, 2024. The company also uses earnings calls to communicate updates; the call for the Third Quarter 2024 results was held on November 14, 2024. You can access all these documents directly via the SEC's EDGAR database or through the company's IR portal.

Future channel: Specialized pharmaceutical distribution network post-approval

This channel is currently theoretical but becomes the most important post-potential FDA approval for commercialization. Right now, there are no concrete, publicly stated numbers regarding a fully established, specialized pharmaceutical distribution network for Panbela Therapeutics, Inc. This will involve establishing relationships with wholesalers, specialty pharmacies, and potentially third-party logistics (3PL) providers capable of handling cold chain or specialized oncology drug logistics. The structure of this channel will be heavily influenced by the final approved indication and geographic reach, but it's the necessary bridge between regulatory approval and patient access.

The current focus is on generating the data that makes this future channel relevant.

Panbela Therapeutics, Inc. (PBLA) - Canvas Business Model: Customer Segments

You're looking at the specific patient populations Panbela Therapeutics, Inc. is targeting with its pipeline assets as of late 2025. This defines who the company is building its commercial and clinical strategy around.

Patients with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC)

This segment is the focus of the Phase III ASPIRE trial, evaluating Ivospemin (SBP-101) in combination with gemcitabine and nab-paclitaxel for patients previously untreated for mPDAC. The trial's safety database included 395 patients as of June 24, 2024. Panbela Therapeutics is seeking to conduct this trial at a target of 60-80 sites globally. Prior clinical studies of SBP-101 in metastatic pancreatic cancer patients showed a median overall survival (OS) of 14.6 months and an objective response rate (ORR) of 48%.

Patients with Familial Adenomatous Polyposis (FAP) requiring surgical delay

This orphan indication targets FAP patients with intact lower gastrointestinal anatomy, using the combination therapy Flynpovi (CPP-1X and sulindac). Data from the FAP-310 trial indicated a 100% risk reduction in the need for lower gastrointestinal (LGI) surgery over up to 48 months when comparing the combination arm to either monotherapy arm (HR = 0.00 for both comparisons). The global FAP treatment market is projected to reach $800 million by 2025.

Oncology specialists and prescribing physicians in cancer treatment centers

These are the key intermediaries and decision-makers who will prescribe Panbela Therapeutics, Inc.'s products upon approval. They are the target for clinical data dissemination, such as the ASPIRE trial interim analysis expected as soon as Q1 2025. The company's Research & Development expenses were $6.0 million in the third quarter of 2024, reflecting investment in trials targeting these specialists.

Patients with STK11 mutant non-small cell lung cancer (NSCLC) in early trials

This segment is being addressed with CPP-1X-S in combination with Keytruda in a Phase I/II trial. This population historically shows a poor response to standard checkpoint inhibitor therapy. In some analyses, STK11 mutations were identified in 8.6% of patients. Data from the Phase I dose escalation study is expected by mid-2025.

Here's a quick look at the patient populations and key associated metrics:

Indication	Product Candidate	Trial Phase/Status	Key Numerical Data Point
mPDAC (First-line)	Ivospemin (SBP-101)	Phase III (ASPIRE Trial)	Safety database included 395 patients (as of June 2024)
FAP (Surgical Delay)	Flynpovi (CPP-1X + sulindac)	Registration Trial Design	100% risk reduction in LGI surgery need in prior trial arm
STK11 mutant NSCLC	CPP-1X-S + Keytruda	Phase I Dose Escalation	Phase I data expected by mid-2025

The company's financial structure in Q3 2024 showed R&D expenses of $6.0 million and a net loss of $7.2 million for the quarter, which supports the ongoing clinical engagement with these customer segments.

The key groups Panbela Therapeutics, Inc. is focused on are:

• Patients with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).
• Patients with Familial Adenomatous Polyposis (FAP) targeting surgical delay.
• Oncology specialists and prescribing physicians in cancer treatment centers.
• Patients with STK11 mutant non-small cell lung cancer (NSCLC) in early trials.

Panbela Therapeutics, Inc. (PBLA) - Canvas Business Model: Cost Structure

You're looking at the hard costs Panbela Therapeutics, Inc. incurs to keep the lights on and, more importantly, to push its clinical pipeline forward. For a pre-revenue biotech, the cost structure is almost entirely driven by R&D and the associated overhead.

The most recent reported operating expenses give us a clear picture of the burn rate leading into late 2025. Research and Development (R&D) expenses, which were $6.0 million in Q3 2024, represent the largest single cost component, reflecting the ongoing investment in the ASPIRE trial and other pipeline activities. General and Administrative (G&A) expenses were approximately $1.1 million in Q3 2024, which management noted was flat compared to the prior year period.

Here's a quick look at the key cost elements based on the latest available figures:

Cost Category	Latest Reported Amount	Period/Context
Research and Development (R&D) Expenses	$6.0 million	Q3 2024
General and Administrative (G&A) Expenses	$1.1 million	Q3 2024
CEO Annual Salary (Post-Reduction)	$30,200	Effective February 2025
CFO Annual Compensation (Post-Reduction)	$23,150	Effective February 2025
CEO Cash Retention Bonus (Contingent)	$186,000	Approved January 2025
CFO Cash Retention Bonus (Contingent)	$105,000	Approved January 2025

Clinical trial operational costs are a major driver within R&D. You should note the operational shift in the ASPIRE trial. In August 2024, the primary Contract Research Organization (CRO) began terminating its relationship due to payment delays, which forced Panbela Therapeutics to assume direct trial responsibility. This transition required specific capital outlay; for instance, a $1.5 million term loan from USWM was specifically used for payment of fees and expenses owed to the CRO for the ASPIRE trial.

Financing costs are a distinct, non-operating expense that impacts cash flow and the balance sheet. The financing secured post-Q3 2024 introduced new interest obligations. The Senior Convertible Promissory Notes from Nant Capital, totaling $12.0 million ($2.85 million Tranche A funded October 22, 2024, and $9.15 million Tranche B expected by November 15, 2024), carry a specific interest structure. These notes earn interest at SOFR + 8% PIK interest (Payment-In-Kind interest), meaning the interest accrues and is added to the principal balance rather than being paid in cash immediately.

Compensation and retention bonuses reflect efforts to secure key personnel through critical milestones. Beyond the significantly reduced base salaries effective February 2025, the Compensation Committee approved specific retention arrangements in January 2025 for key employees:

• CEO and President Jennifer K. Simpson is eligible for a cash retention bonus of $186,000.
• VP of Finance and CFO Susan Horvath is eligible for a cash retention bonus of $105,000.

These bonuses are contingent upon remaining employed through the earliest of several conditions, including achieving an unrestricted cash balance exceeding $10,000,000 or reaching December 31, 2025.

The cost structure is further detailed by these operational and financial items:

• The US WorldMeds note was paid off immediately upon receipt of the Tranche A Nant Capital funds.
• The Nant Capital Notes mature in six months from issuance.
• The notes are convertible to common stock at $0.37 per share, subject to a 33.33% ownership cap until maturity.

Finance: draft 13-week cash view by Friday.

Panbela Therapeutics, Inc. (PBLA) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Panbela Therapeutics, Inc. (PBLA) as of late 2025. For a clinical-stage biopharmaceutical company, the revenue picture is almost entirely about non-operating cash flow until a drug gets the green light from the FDA.

Currently, Panbela Therapeutics, Inc. has no product revenue because its key assets, Ivospemin (SBP-101) and Flynpovi™, remain in clinical development. The focus is on hitting milestones, not shipping product.

The near-term financial reality is that operating cash flow is negative, driven by significant Research and Development expenses, like those tied to the ASPIRE trial. For example, cash used in operations for the nine months ended September 30, 2024, totaled approximately $12.5 million. You have to look at financing activities to see where the cash to fund operations is coming from.

Future revenue streams are entirely contingent on regulatory success and subsequent commercialization. These are the two primary potential product revenue sources:

• Future revenue from sales of Ivospemin (SBP-101) post-regulatory approval, primarily targeting metastatic pancreatic ductal adenocarcinoma (mPDAC) and other indications.
• Future revenue from sales of Flynpovi™, which is being developed for Familial Adenomatous Polyposis (FAP).

To keep the lights on and fund the clinical path-especially with the ASPIRE trial interim analysis being tracked for Q1 2025-Panbela Therapeutics, Inc. relies on proceeds from equity and debt financing. This is the most concrete financial data we have for the revenue stream block right now.

A significant recent infusion was the strategic financing from Nant Capital, LLC, which was a $12.0 million commitment announced in late 2024. This wasn't all at once, mind you; it was structured to provide staged support.

Here's a quick look at the components of that recent financing, which is critical for understanding the current cash runway:

Financing Event/Source	Date of Agreement/Funding	Principal Amount
Nant Capital Tranche A Note	October 22, 2024	$2,850,000
Nant Capital Tranche B Note (Expected)	On or before November 15, 2024	$9,150,000
Total Nant Capital Commitment	Late October 2024	$12,000,000
Subordinated Promissory Notes (Q3 2024)	During Q3 2024	$700,000
Registered Public Offering (Gross Proceeds)	January 31, 2024	Approximately $9.0 million

What this estimate hides is the burn rate; cash on hand as of September 30, 2024, was only about $142,000 before the Nant Capital funds hit, so these financing proceeds are the lifeblood. Also, remember that the $12.0 million from Nant Capital is structured as convertible promissory notes, meaning it's debt that converts to equity, not pure revenue.

You should also track other potential, non-product inflows, though they are less certain than the financing activities. For instance, in April 2024, Panbela Therapeutics, Inc.'s partner in Pediatric Neuroblastoma, US WorldMeds®, provided a non-dilutive payment of approximately $0.8 million in exchange for a reduction in potential future milestone payments. That's a small, one-time bump, not a sustainable stream.

Finance: draft 13-week cash view by Friday.